Follow
Janine Roney
Janine Roney
Manager Research Dept Infectious Diseases Alfred Hopsital & Monash Univeristy
Verified email at monash.edu
Title
Cited by
Cited by
Year
Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy
JH Elliott, F Wightman, A Solomon, K Ghneim, J Ahlers, MJ Cameron, ...
PLoS pathogens 10 (11), e1004473, 2014
5482014
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study
JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, ...
The lancet HIV 2 (12), e520-e529, 2015
2562015
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
SMART Study Group*
Annals of internal medicine 149 (5), 289-299, 2008
1672008
Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs
AJ Wade, JS Doyle, E Gane, C Stedman, B Draper, D Iser, SK Roberts, ...
Clinical Infectious Diseases 70 (9), 1900-1906, 2020
942020
Point-of-care hepatitis C testing from needle and syringe programs: an Australian feasibility study
B Williams, J Howell, J Doyle, AJ Thompson, B Draper, C Layton, ...
International Journal of Drug Policy 72, 91-98, 2019
512019
Experiences and expectations of participants completing an HIV cure focused clinical trial
JH McMahon, JH Elliott, J Roney, M Hagenauer, SR Lewin
Aids 29 (2), 248-250, 2015
312015
Favipiravir in early symptomatic COVID-19, a randomised placebo-controlled trial
JH McMahon, JSY Lau, A Coldham, J Roney, M Hagenauer, S Price, ...
EClinicalMedicine 54, 2022
272022
Microelimination of hepatitis C among people with human immunodeficiency virus coinfection: declining incidence and prevalence accompanying a multicenter treatment scale-up trial
JS Doyle, DK van Santen, D Iser, J Sasadeusz, M O’Reilly, B Harney, ...
Clinical Infectious Diseases 73 (7), e2164-e2172, 2021
252021
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV 2: e520–e529
JH Elliott, JH McMahon, CC Chang, SA Lee, W Hartogensis, N Bumpus, ...
232015
HealthMap: a cluster randomised trial of interactive health plans and self-management support to prevent coronary heart disease in people with HIV
S Dodson, KM Klassen, K McDonald, T Millard, RH Osborne, ...
BMC infectious diseases 16, 1-11, 2016
182016
A clinical trial of non-invasive imaging with an anti-HIV antibody labelled with copper-64 in people living with HIV and uninfected controls
JH McMahon, JM Zerbato, JSY Lau, JL Lange, M Roche, C Tumpach, ...
EBioMedicine 65, 2021
162021
The impact of point‐of‐care hepatitis C testing in needle and syringe exchange programs on linkage to care and treatment uptake among people who inject drugs: An Australian …
J Howell, MW Traeger, B Williams, C Layton, JS Doyle, N Latham, ...
Journal of viral hepatitis 29 (5), 375-384, 2022
132022
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy
TM Mota, TA Rasmussen, A Rhodes, S Tennakoon, A Dantanarayana, ...
AIDS 31 (8), 1137-1141, 2017
132017
Community-based provision of direct-acting antiviral therapy for hepatitis C: study protocol and challenges of a randomized controlled trial
AJ Wade, JS Doyle, E Gane, C Stedman, B Draper, D Iser, SK Roberts, ...
Trials 19, 1-9, 2018
102018
Micro-elimination of hepatitis C among people with HIV coinfection: declining incidence and prevalence accompanying a multi-center treatment scale-up trial
JS Doyle, DK van Santen, D Iser, J Sasadeusz, M O’Reilly, B Harney
Clin Infect Dis 3, 2020
82020
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count> or= 300 cells/microL who were assigned to 7.5 MIU interleukin-2.
Z Fox, F Antunes, R Davey, B Gazzard, N Klimas, A Labriola, M Losso, ...
HIV medicine 8 (2), 112-123, 2007
72007
Surveillance testing using salivary RT-PCR for SARS-CoV-2 in managed quarantine facilities in Australia: A laboratory validation and implementation study
A Jenney, D Chibo, M Batty, J Druce, R Melvin, A Stewardson, ...
The Lancet Regional Health–Western Pacific 26, 2022
52022
An adaptive randomised placebo controlled phase II trial of antivirals for COVID-19 infection (VIRCO): A structured summary of a study protocol for a randomised controlled trial.
JH McMahon, JSY Lau, J Roney, BA Rogers, J Trubiano, J Sasadeusz, ...
Trials, 847-847, 2020
52020
FRI-228-Community-based hepatitis C treatment of people who inject drugs and their injecting network is feasible and effective: Results from the TAP (Treatment And Prevention …
J Doyle, P Dietze, M Stoove, P Higgs, P Desmond, D Iser, E Mcbryde, ...
Journal of Hepatology 70 (1), e495, 2019
52019
the rapid-eC study–a feasibility study of point-of-care testing in community clinics targeted to people who inject drugs in Melbourne, Australia
B Williams, A Pedrana, J Howell, J Doyle, A Thompson, F Bramwel, ...
Journal of Hepatology 68, S313-S314, 2018
52018
The system can't perform the operation now. Try again later.
Articles 1–20